BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK...
BC Extra | Oct 11, 2019
Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

The tepid performances of two high-profile IPOs late in the week added to a widening body of evidence that investors’ demand for new biotech listings has begun to weaken, despite a long queue of companies...
BC Extra | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos --...
BC Innovations | Aug 29, 2019
Translation in Brief

Cytomegalovirus vectors for a prophylactic HIV vaccine

A spread-deficient cytomegalovirus carrying SIV antigens evoked long-term protective immunity against successive SIV infections in monkeys, suggesting that a prophylactic HIV vaccine can be developed in humans using a similar strategy. While academics and companies...
BC Extra | Mar 22, 2019
Financial News

Hookipa proposes IPO as its cancer vaccines head towards the clinic

Infectious disease and cancer vaccine company Hookipa proposed Friday to raise up to $86.3 million in an IPO on NASDAQ. Hookipa Pharma Inc. (New York, N.Y.) is developing vaccines using its VaxWave and TheraT viral...
BioCentury | May 11, 2018
Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
BC Week In Review | Jan 26, 2018
Clinical News

Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. The...
BC Extra | Jan 22, 2018
Clinical News

Astellas/Vical CMV vaccine fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical sank...
BC Week In Review | Sep 26, 2016
Clinical News

Cytomegalovirus: Phase II data

Top-line data from a double-blind, international Phase II trial in 150 CMV-seronegative kidney transplant recipients receiving an organ from a CMV-seropositive donor showed that 5 mg intramuscular ASP0113 missed the primary endpoint of reducing the...
Items per page:
1 - 10 of 41